Change in circulating levels of the chemokines macrophage inflammatory proteins 1α and 1β, RANTES, monocyte chemotatic protein-1 and interleukin-16 following treatment of severely immunodeficient HIV-infected individuals with indinavir

AIDS

Volumn 11, Issue 4, 1997, Pages 485-491

  Bisset, Leslie R ^a   Rothen, Madeleine ^a   Joller Jemelka, Helen I ^a   Dubs, Rolf W ^a   Grob, Peter J ^a   Opravil, Milos ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Antiviral therapy; Cellular factors; Cytokines; HIV protease inhibitors; HIV 1

Indexed keywords

ANTIVIRUS AGENT; INDINAVIR; INTERLEUKIN 16; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE; VIRUS REPLICATION;

EID: 0031055461     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199704000-00012     Document Type: Article

References (26)

1. + T cells, Immunol Today 1996, 17:217-224.
2. Yap KL, Ada GL, McKenzie IFC: Transfer of specific cytotoxic T lymphocytes protect mice inoculated with the influenza virus. Nature 1978, 273:238-240.
3. Mackewicz CE, Ortega HW, Levy JA: CD8+ cell anti-HIV activity correlates with the clinical state of the infected individual. J Clin Invest 1991, 87:1462-1466.
4. Mackewicz C, Levy JA: CD8+ cell anti-HIV activity: nonlytic suppression of virus replication. AIDS Res Human Retrovirus 1992, 8:1039-1050.
5. Walker CM, Moody DJ, Stites DP, Levy JA: CD8+ lymphocytes can control HIV infection in vitro by suppressing virus replication. Science 1986, 234:1563-1566.
6. Walker CM, Levy JA: A diffusable lymphokine produced by CD8+ lymphocytes suppresses HIV replication. Immunology 1989, 66:628-630.
7. Cocchi F, DeVico AL, Garzino-Demo A, Arya SK, Gallo RC, Lusso P: Identification of RANTES, MIP-1a, and MIP-1b as the major HIV-suppressive factors produced by CD8+ T cells. Science 1995, 270:1811-1815.
8. Alkhatih G, Combadiere C, Broder CC, et al.: CC CKR5: a RANTES, MIP-1a, MIP-1b receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 1996, 272:1955-1958.
9. Choe H, Farzan M, Sun Y, et al.: The b-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 1996, 86:1135-1148.
10. Deng H-K, Liu R, Ellmeier W, et al.: Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996, 381:661-666.
11. Doranz BJ, Rucker J, Yi Y, et al.: A dual-tropic, primary HIV-1 isolate that uses fusin and the b-chemokine receptors CKR-5, CKR-2b as fusion cofactors. Cell 1996, 86:1149-1159.
12. Dragic T, Litwin V, Allaway GP, et al.: HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996, 381:667-673.
13. Weiss RA, Clapham PR: Hot fusion of HIV. Nature 1996, 381:647-648.
14. Baier M, Werner A, Bannert N, Metzner K, Kurth R: HIV suppression by interleukin-16. Nature 1995, 378:563.
15. Center DM, Kornfeld H, Cruikshank WW: Interleukin 16 and its function as a CD4 ligand. Immunol Today 1996, 17:476-481.
16. Poli G, Biswas P, Delfanti F, et al.: Chemokines regulate endogenous HIV replication: enhancement by MCP-1 and suppression by RANTES. XI International Conference on AIDS. Vancouver, 1996 [abstract Tu.A.392].
17. Biswas P, Delfanti F, Vicenzi E, et al.: Secretion of multiple chemokines in U1 cells: autocrine upregulation of viral expression by MCP-1. XI International Conference on AIDS. Vancouver, July 1996 [abstract Mo.A.145].
18. McKenzie SW, Dallalio C, North M, Frame P, Means RT: Serum chemokine levels in patients with non-progressing infection. AIDS 1996, 10:F29-F33.
19. Zanussi S, D' Andrea M, Simonelli C, Tirelli U, De Paoli P: Serum levels of RANTES and MIP-1α in HIV-positive long-term survivors and progressor patients [letter]. AIDS 1996, 10:1431-1432.
20. Schmidtmayerova H, Nottet HSLM, Nuovo G, et al.: Human immunodeficiency virus type 1 infection alters chemokine b peptide expression in human monocytes: implications for recruitment of leukocytes into brain and lymph nodes. Proc Natl Acad Sci USA 1996, 93:700-704.
21. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M: Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995, 373:123-126.
22. Wei X, Ghosh SK, Taylor ME, et al.: Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995, 373:117-122.
23. Stein DS, Fish DG, Bilello JA, Preston SL, Martineau GL, Drusano GL: A 24-week open-label Phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir), AIDS 1996, 10:485-492.
24. Kelleher AD, Carr A, Zaunders J, Cooper DA: Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir. J Infect Dis 1996, 173:321-329.
25. Conlon K, Lloyd A, Chattopadhyay U, et al.: CD8+ and CD45RA+ human peripheral blood lymphocytes are potent sources of macrophage inflammatory protein 1a, interleukin-8 and RANTES. Eur J Immunol 1995, 25:751-756.
26. Schuitemaker H, Koot M, Kootstra NA, et al.: Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic population. J Virol 1992, 66:1354-1360.